{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:45:09Z","timestamp":1790084709213,"version":"4.0.1"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Lipoprotein(a) [Lp(a)] is a complex polymorphic lipoprotein comprised of a low-density lipoprotein particle with one molecule of apolipoprotein B100 and an additional apolipoprotein(a) connected through a disulfide bond. The serum concentration is mostly genetically determined and only modestly influenced by diet and other lifestyle modifications. In recent years it has garnered increasing attention due to its causal role in pre-mature atherosclerotic cardiovascular disease and calcific aortic valve stenosis, while novel effective therapeutic options are emerging [apolipoprotein(a) antisense oligonucleotides and ribonucleic acid interference therapy]. Bibliometric descriptive analysis and mapping of the research literature were made using Scopus built-in services. We focused on the distribution of documents, literature production dynamics, most prolific source titles, institutions, and countries. Additionally, we identified historical and influential papers using Reference Publication Year Spectrography (RPYS) and the CRExplorer software. An analysis of author keywords showed that Lp(a) was most intensively studied regarding inflammation, atherosclerosis, cardiovascular risk assessment, treatment options, and hormonal changes in post-menopausal women. The results provide a comprehensive view of the current Lp(a)-related literature with a specific interest in its role in calcific aortic valve stenosis and potential emerging pharmacological interventions. It will help the reader understand broader aspects of Lp(a) research and its translation into clinical practice.<\/jats:p>","DOI":"10.3389\/fpubh.2022.923797","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T05:51:45Z","timestamp":1657000305000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study"],"prefix":"10.3389","volume":"10","author":[{"given":"David","family":"\u0160uran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Bla\u017eun Vo\u0161ner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jernej","family":"Zavr\u0161nik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreja","family":"Sinkovi\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojko","family":"Kani\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Kokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franjo","family":"Naji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadej","family":"Zavr\u0161nik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein (a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat Rev Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10557-019-06906-9","article-title":"Lipoprotein(a) and atherosclerotic cardiovascular disease: current understanding and future perspectives","volume":"33","author":"Wu","year":"2019","journal-title":"Cardiovasc Drugs Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2741\/4635","article-title":"Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein","volume":"23","author":"Saeed","year":"2018","journal-title":"Front Biosci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2018.12.014","article-title":"Remnant lipoproteins and atherosclerotic cardiovascular disease","volume":"490","author":"Tada","year":"2019","journal-title":"Clin Chim Acta."},{"key":"B5","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.nedt.2015.01.002","article-title":"Research literature production on nursing competences from 1981 till 2012: a bibliometric snapshot","volume":"35","author":"Bla\u017eun","year":"2015","journal-title":"Nurse Educ Today."},{"key":"B8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/hir.12295","article-title":"Application of bibliometrics in medicine: a historical bibliometrics analysis","volume":"38","author":"Kokol","year":"2021","journal-title":"Health Info Libr J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1108\/eb026482","article-title":"Statistical bibliography or bibliometrics?","volume":"25","author":"Pritchard","year":"1969","journal-title":"J Doc."},{"key":"B10","first-page":"120","article-title":"Bibliometrics of electronic journals in information science","volume":"7","author":"Hawkins","year":"2001","journal-title":"Inf Res Int Electron J."},{"key":"B11","unstructured":"KokolP\n            KokolM\n            ZagoranskiS\n          35220816Machine Learning on Small Size Samples: A Synthetic Knowledge Synthesis2021"},{"key":"B12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2018.04.017","article-title":"Mapping the European cancer research landscape: an evidence base for national and Pan-European research and funding","volume":"100","author":"Begum","year":"2018","journal-title":"Eur J Cancer."},{"key":"B13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"B14","first-page":"285","article-title":"\u201cVisualizing bibliometric networks","volume-title":"Measuring Scholarly Impact: Methods and Practice","author":"van Eck","year":""},{"key":"B15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/knowledge2020011","article-title":"Knowledge development in artificial intelligence use in pediatrics","volume":"2","author":"Kokol","year":"2022","journal-title":"Knowledge"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3402\/qhw.v9.26152","article-title":"What can \u201cthematic analysis\u201d offer health and wellbeing researchers?","volume":"9","author":"Braun","year":"2014","journal-title":"Int J Qual Stud Health Well"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15323269.2018.1509193","article-title":"Bibliographic-based identification of hot future research topics: an opportunity for hospital librarianship","volume":"4","author":"Kokol","year":"2018","journal-title":"J Hosp Librariansh."},{"key":"B18","first-page":"59","article-title":"Some account of a disorder of the breast","volume-title":"Medical Transactions","author":"Heberden","year":"1772"},{"key":"B19","first-page":"1","article-title":"Ueber experimentelle cholesterinsteatose und ihre Bedeutung fur die Entstehung einiger pathologischer prozesse","volume":"24","author":"Anichkov","year":"1913","journal-title":"Zbl Allg Path"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1194\/jlr.R043414","article-title":"In celebration of the 100th anniversary of the lipid hypothesis of atherosclerosis","volume":"54","author":"Steinberg","year":"2013","journal-title":"J Lipid Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in. man\u2013the LP system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand."},{"key":"B22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"B23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein (a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1001\/jama.1993.03510180065035","article-title":"A prospective study of lipoprotein (a) and the risk of myocardial infarction","volume":"270","author":"Ridker","year":"1993","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation."},{"key":"B26","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and Non-vascular mortality","volume":"302","author":"Emerging Risk Factors","year":"2009","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein (a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B29","first-page":"89","article-title":"Lipoprotein(a)","volume":"41","author":"Thuillier","year":"1983","journal-title":"Ann Biol Clin"},{"key":"B30","first-page":"1","article-title":"Apolipoproteins and lipoproteins of human plasma: significance in health and in disease","volume":"20","author":"Kostner","year":"1983","journal-title":"Adv Lipid Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcvm.2021.672913","article-title":"Cardiac rehabilitation: a bibliometric review from 2001 to 2020","volume":"8","author":"Yuan","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.5195\/jmla.2018.181","article-title":"Discrepancies among scopus, web of science, and pubmed coverage of funding information in medical journal articles","volume":"106","author":"Kokol","year":"2018","journal-title":"J Med Libr Assoc."},{"key":"B33","unstructured":"Blazun Vo\u0161nerH\n            KokolP\n          Journals Bibliometric Portfolios; Case of Nursing Research. Library Philosophy Practice (e-journal)2019"},{"key":"B34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.5551\/jat.RV17001","article-title":"Role of NLRP3 inflammasomes in atherosclerosis","volume":"24","author":"Karasawa","year":"2017","journal-title":"J Atheroscler Thromb."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102034","article-title":"New insights into the role of inflammation in the pathogenesis of atherosclerosis","author":"Wu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1002\/jcp.25930","article-title":"NLRP3 inflammasome: its regulation and involvement in atherosclerosis","volume":"233","author":"Hoseini","year":"2018","journal-title":"J Cell Physiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.119.316206","article-title":"Atherogenic lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation","volume":"126","author":"Schnitzler","year":"2020","journal-title":"Circ Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1210\/jc.2015-1096","article-title":"Elevated lipoprotein(a) does not cause low-grade inflammation despite causal association with aortic valve stenosis and myocardial infarction: a study of 100 578 individuals from the general population","volume":"100","author":"Langsted","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1001\/jamacardio.2020.2413","article-title":"Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE trial","volume":"5","author":"Puri","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.amjcard.2021.03.038","article-title":"Impact of Post-procedural high-sensitivity C-reactive protein on lipoprotein(a)-associated cardiovascular risk with ST-segment elevation myocardial infarction with percutaneous coronary intervention","volume":"150","author":"Wang","year":"2021","journal-title":"Am J Cardiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.thromres.2011.07.001","article-title":"Interaction between homocysteine and lipoprotein (a) increases the prevalence of coronary artery disease\/myocardial infarction in women: a case-control study","volume":"129","author":"Balogh","year":"2012","journal-title":"Thromb Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jacbts.2017.03.015","article-title":"Lipoprotein(a) induces human aortic valve interstitial cell calcification","volume":"2","author":"Yu","year":"2017","journal-title":"JACC Basic Transl Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12944-019-1092-6","article-title":"Prognostic value of lipoprotein (a) level in patients with coronary artery disease: a meta-analysis","volume":"18","author":"Wang","year":"2019","journal-title":"Lipids Health Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.107.719369","article-title":"Symptomatic peripheral arterial disease in women: Non-traditional biomarkers of elevated risk","volume":"117","author":"Pradhan","year":"2008","journal-title":"Circulation."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1161\/01.STR.0000222666.21482.b6","article-title":"Lipoprotein(a) and incident ischemic stroke: the atherosclerosis risk in communities (ARIC) study","volume":"37","author":"Ohira","year":"2006","journal-title":"Stroke."},{"key":"B52","doi-asserted-by":"publisher","first-page":"15660","DOI":"10.1038\/s41598-021-95141-0","article-title":"Lipoprotein (a) level as a risk factor for stroke and its subtype: a systematic review and meta-analysis","volume":"11","author":"Kumar","year":"2021","journal-title":"Sci Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/metabo11070459","article-title":"Lipoprotein proteomics and aortic valve transcriptomics identify biological pathways linking lipoprotein(a) levels to aortic stenosis","volume":"11","author":"Bourgeois","year":"2021","journal-title":"Metabolites."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e011781","DOI":"10.1161\/JAHA.118.011781","article-title":"Lipoprotein(a) particle production as a determinant of plasma lipoprotein(a) concentration across varying apolipoprotein(a) isoform sizes and background cholesterol-lowering therapy","volume":"8","author":"Chan","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B57","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jacc.2015.05.066","article-title":"Calcification in aortic stenosis: the skeleton key","volume":"66","author":"Pawade","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e480784","DOI":"10.1155\/2012\/480784","article-title":"A systematic literature review of the association of lipoprotein(a) and autoimmune diseases and atherosclerosis","volume":"2012","author":"Missala","year":"2012","journal-title":"Int J Rheumatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/14728222.2019.1620206","article-title":"An in-depth analysis shows a hidden atherogenic lipoprotein profile in Non-diabetic chronic kidney disease patients","volume":"23","author":"Bermudez-Lopez","year":"2019","journal-title":"Expert Opin Ther Targets."},{"key":"B61","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.maturitas.2020.03.007","article-title":"Menopause symptom management in women with dyslipidemias: an EMAS clinical guide","volume":"135","author":"Anagnostis","year":"2020","journal-title":"Maturitas."},{"key":"B62","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/postgradmedj-2019-136591","article-title":"Lipoprotein(a) and coronary artery disease in Chinese Post-menopausal female patients: a large cross-sectional cohort study","volume":"95","author":"Liu","year":"2019","journal-title":"Postgrad Med J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2019.10.005","article-title":"Effect of hormone replacement therapy on atherogenic lipid profile in Post-menopausal women","volume":"184","author":"Gregersen","year":"2019","journal-title":"Thromb Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nature05487","article-title":"Mechanisms linking obesity with cardiovascular disease","volume":"444","author":"Van Gaal","year":"2006","journal-title":"Nature."},{"key":"B66","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12933-017-0520-z","article-title":"Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature","volume":"16","author":"Paige","year":"2017","journal-title":"Cardiovasc Diabetol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2018.12.022","article-title":"Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: the atherosclerosis risk in communities study","volume":"282","author":"Saeed","year":"2019","journal-title":"Atherosclerosis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"633529","DOI":"10.3389\/fendo.2021.633529","article-title":"Association between lipoprotein (A) and diabetic nephropathy in patients with type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Ren","year":"2021","journal-title":"Front Endocrinol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jacl.2015.11.010","article-title":"A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality","volume":"10","author":"Wadhera","year":"2016","journal-title":"J Clin Lipidol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0167-5273(02)00195-X","article-title":"Beyond lipid lowering: the role of statins in vascular protection","volume":"86","author":"Liao","year":"2002","journal-title":"Int J Cardiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jacc.2008.10.024","article-title":"Meta-analysis of the relationship between Non\u2013high-density lipoprotein cholesterol reduction and coronary heart disease risk","volume":"53","author":"Robinson","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"23","DOI":"10.14797\/mdcj-15-1-23","article-title":"Statins: then and now","volume":"15","author":"Toth","year":"2019","journal-title":"Methodist Debakey Cardiovasc J."},{"key":"B73","doi-asserted-by":"publisher","first-page":"105735","DOI":"10.1016\/j.biocel.2020.105735","article-title":"Statins reduce vascular inflammation in atherogenesis: a review of underlying molecular mechanisms","volume":"122","author":"Liberale","year":"2020","journal-title":"Int J Biochem Cell Biol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein (a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1373\/clinchem.2019.306738","article-title":"Effect of lipoprotein(a) on the diagnosis of familial hypercholesterolemia: does it make a difference in the clinic?","volume":"65","author":"Chan","year":"2019","journal-title":"Clin Chem."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"JACC"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J Lipid Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e016839","DOI":"10.1161\/JAHA.120.016839","article-title":"Effects of evolocumab on low-density lipoprotein cholesterol, Non-high density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) by race and ethnicity: a meta-analysis of individual participant data from double-blind and open-label extension studies","volume":"10","author":"Daviglus","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B80","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL apheresis","volume":"198","author":"Thompson","year":"2008","journal-title":"Atherosclerosis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms[S]","volume":"58","author":"Mack","year":"2017","journal-title":"J Lipid Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/ATVBAHA.120.314965","article-title":"Genome-wide association study highlights APOH as a novel locus for lipoprotein(a) levels-brief report","volume":"41","author":"Hoekstra","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jacl.2017.10.024","article-title":"Temporal variability in lipoprotein (a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials","volume":"12","author":"Marcovina","year":"2018","journal-title":"J Clin Lipidol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tips.2019.01.004","article-title":"New frontiers in Lp(a)-targeted therapies","volume":"40","author":"Borrelli","year":"2019","journal-title":"Trends Pharmacol Sci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein (a) concentration, and coronary artery disease: a mendelian randomization analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein (a) kringle 4 domains on immunochemical measurements of lipoprotein (a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin Chem."},{"key":"B88","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.thromres.2006.03.002","article-title":"Lipoprotein (a) in patients with spontaneous venous thromboembolism","volume":"120","author":"Vormittag","year":"2007","journal-title":"Thromb Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"e013020","DOI":"10.1161\/JAHA.119.013020","article-title":"apoB\/apoA-I ratio and Lp(a) associations with aortic valve stenosis incidence: insights from the EPIC-norfolk prospective population study","volume":"8","author":"Zheng","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B91","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jacc.2018.04.064","article-title":"Hemodynamic deterioration of surgically implanted bioprosthetic aortic valves","volume":"72","author":"Salaun","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jacbts.2020.05.004","article-title":"Genetic and In vitro inhibition of PCSK9 and calcific aortic valve stenosis","volume":"5","author":"Perrot","year":"2020","journal-title":"JACC Basic Transl Sci."},{"key":"B93","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.jacc.2018.09.063","article-title":"PCSK9 involvement in aortic valve calcification","volume":"72","author":"Poggio","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-021-10138-4","article-title":"Plasmatic PCSK9 levels are associated with very fast progression of asymptomatic degenerative aortic stenosis","author":"Mateos","year":"2021","journal-title":"J Cardiovasc Trans Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ihj.2021.01.017","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors in aortic stenosis\u2014is this the light at the end of the tunnel for patients with aortic stenosis?","volume":"73","author":"Agstam","year":"2021","journal-title":"Indian Heart J."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.923797\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T05:51:55Z","timestamp":1657000315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.923797\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":95,"alternative-id":["10.3389\/fpubh.2022.923797"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.923797","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"article-number":"923797"}}